Entity

Time filter

Source Type

New York City, New York, United States

Patent
International Aids Vaccine Initiative and Scripps Research Institute | Date: 2015-03-10

The present application relates to immunogens of broadly neutralizing monoclonal antibodies specific for HIV-1, such as broad and potent neutralizing monoclonal antibodies specific for HIV-1 and their gernation and methods of use. Broad neutralization suggests that the antibodies can neutralize HIV-1 isolates from different individuals. Immunogens or vaccines which may elicit such antibody associated responses are useful in pharmaceutical compositions for the prevention and treatment of HIV, and for the diagnosis and monitoring of HIV infection.


Patent
International Aids Vaccine Initiative | Date: 2013-03-10

The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.


Patent
International Aids Vaccine Initiative, Scripps Research Institute and Cornell University | Date: 2015-06-05

The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC


Patent
International Aids Vaccine Initiative, Scripps Research Institute and Cornell Center For Technology Enterprise And Commercialization | Date: 2013-11-05

The present application relates to novel HIV-1 envelope glycoproteins, which may be utilized as HIV-1 vaccine immunogens, and antigens for crystallization, electron micrsocopy and other biophysical, biochemical and immunological studies for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions, which are formulated into the vaccines of the present invention.


Patent
International Aids Vaccine Initiative and Scripps Research Institute | Date: 2015-07-30

The present invention relates to using HIV-1 broadly neutralizing antibodies to screen for glycan-dependent or protein-dependent self reactivities inherent in these mutated antibodies, and defining this cross recognition at the molecular level, and utilizing the information to re-elicit trimer-specific and/or N-glycan-dependent or protein-surface-dependent broadly neutralizing antibodies and therapeutic applications thereof.

Discover hidden collaborations